Berliner Boersenzeitung - US drugmaker Eli Lilly says slashing insulin prices by 70%

EUR -
AED 4.095102
AFN 72.480008
ALL 90.801688
AMD 402.807486
ANG 1.995737
AOA 1023.635334
ARS 1721.721299
AUD 1.61933
AWG 2.007127
AZN 1.900047
BAM 1.955836
BBD 2.250342
BDT 139.162586
BGN 1.948955
BHD 0.422108
BIF 3342.96213
BMD 1.115071
BND 1.431727
BOB 13.402249
BRL 6.138357
BSD 1.117321
BTN 104.873949
BWP 15.391286
BYN 3.345962
BYR 21855.38619
BZD 2.247142
CAD 1.573644
CDF 2586.964483
CHF 0.914162
CLF 0.027822
CLP 1094.980351
CNY 7.444774
CNH 7.438418
COP 3608.76707
CRC 506.709417
CUC 1.115071
CUP 26.815498
CVE 110.267049
CZK 24.346956
DJF 198.963698
DKK 7.480457
DOP 67.891262
DZD 151.940824
EGP 59.957114
ERN 16.726061
ETB 183.378708
FJD 2.526309
FKP 0.834974
GBP 0.834166
GEL 2.893653
GGP 0.834974
GHS 13.055243
GIP 0.834974
GMD 83.077063
GNF 9896.183924
GTQ 8.538159
GYD 234.234353
HKD 8.744429
HNL 30.029558
HRK 7.547925
HTG 146.432722
HUF 363.51345
IDR 20192.258205
ILS 3.552538
IMP 0.834974
INR 104.716854
IQD 1693.83148
IRR 2108992.359359
ISK 136.919964
JEP 0.834974
JMD 177.323296
JOD 0.790629
JPY 176.710877
KES 145.192698
KGS 97.510486
KHR 4552.084602
KMF 492.86165
KPW 1003.563608
KRW 1520.737678
KWD 0.346765
KYD 0.931217
KZT 500.809308
LAK 25136.46717
LBP 100053.859534
LKR 371.556906
LRD 189.94353
LSL 18.477643
LTL 3.292514
LVL 0.674496
LYD 7.150133
MAD 10.921803
MDL 19.971371
MGA 5077.094359
MKD 61.556144
MMK 2341.587311
MNT 4015.514918
MOP 9.019368
MRU 45.108838
MUR 52.442198
MVR 17.176258
MWK 1937.436008
MXN 20.766565
MYR 4.528864
MZN 71.257178
NAD 18.477643
NGN 1502.23485
NIO 41.120764
NOK 10.548462
NPR 167.798119
NZD 2.015128
OMR 0.428348
PAB 1.117421
PEN 3.848972
PGK 5.092095
PHP 70.369926
PKR 309.016043
PLN 4.399568
PYG 6984.129802
QAR 4.084276
RON 5.343646
RSD 117.622186
RUB 91.352798
RWF 1649.13065
SAR 4.188587
SBD 8.974739
SCR 15.358485
SDG 670.719139
SEK 11.033072
SGD 1.430306
SHP 0.835103
SLE 25.591287
SLL 23382.48045
SOS 638.511867
SRD 41.908265
STD 23079.712667
STN 24.500455
SVC 9.776182
SYP 14498.149201
SZL 18.471343
THB 37.411034
TJS 10.307092
TMT 3.902748
TND 3.343362
TOP 2.684822
TRY 55.9111
TTD 7.577141
TWD 36.546782
TZS 2952.454872
UAH 50.616941
UGX 4570.084937
USD 1.115071
UYU 44.950835
UZS 13332.247784
VES 999.456181
VND 28526.296796
VUV 132.393741
WST 3.108622
XAF 655.957
XAG 0.021465
XAU 0.000274244363
XCD 3.013535
XCG 2.013637
XDR 0.788413
XOF 655.957
XPF 119.331742
YER 263.853652
ZAR 18.420333
ZMK 10036.978597
ZMW 22.703422
ZWL 359.052318
SSP 6406.340367
MXV 2.33632
  • CMSD

    -0.1200

    19.81

    -0.61%

  • JRI

    0.0000

    10.77

    0%

  • BCC

    -1.8200

    74.15

    -2.45%

  • CMSC

    -0.2228

    19.53

    -1.14%

  • BCE

    0.2000

    20.34

    +0.98%

  • RIO

    0.0100

    94.17

    +0.01%

  • AZN

    -2.7400

    161.47

    -1.7%

  • GSK

    -1.1800

    48.17

    -2.45%

  • RBGPF

    0.0000

    65

    0%

  • NGG

    0.8800

    75.82

    +1.16%

  • RYCEF

    -0.7300

    19.08

    -3.83%

  • BTI

    -0.4500

    54.4

    -0.83%

  • BP

    0.4700

    43.99

    +1.07%

  • RELX

    -0.0600

    33.18

    -0.18%

  • VOD

    -0.1800

    16.15

    -1.11%

US drugmaker Eli Lilly says slashing insulin prices by 70%
US drugmaker Eli Lilly says slashing insulin prices by 70% / Photo: FREDERICK FLORIN - AFP/File

US drugmaker Eli Lilly says slashing insulin prices by 70%

US pharmaceutical giant Eli Lilly announced Wednesday it was cutting the cost of its most commonly prescribed insulins by 70 percent after years of soaring prices that hit millions of Americans living with diabetes.

Text size:

The announcement comes as the cost of insulin has surged in recent years, with demand increasing significantly as well.

"Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system," the Indianapolis-based drugmaker said in a statement.

The company added it would cut the price of its non-branded insulin to $25 a vial starting May 1.

It will also lower the price of Humalog, its most commonly prescribed insulin, and Humulin, by 70 percent starting in the fourth quarter of this year.

"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said Lilly CEO David Ricks.

The company also said Wednesday it would automatically cap out-of-pocket costs at certain retail pharmacies at $35, for people with commercial insurance using Lilly insulin.

Diabetes is one of the fastest-growing chronic diseases globally, according to a 2022 study.

- Soaring prices -

In recent decades, insulin prices have soared in the United States, costing over eight times more than in 32 comparable high-income countries, a 2020 Rand Corporation study found.

But the cost of producing insulin is relatively low compared to the sale price.

A survey by nonprofit T1International also showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.

In his State of the Union address last month, President Joe Biden said: "Big Pharma has been unfairly charging people hundreds of dollars –- and making record profits. Not anymore."

While seniors on Medicare have the cost of insulin capped, millions of other Americans not on the federal health insurance program for the elderly need insulin to save their lives, he added.

"Let's finish the job this time. Let's cap the cost of insulin at $35 a month for every American who needs it," Biden said.

Diabetes is divided into two types. An estimated nine million people have type 1 diabetes, a chronic condition where the pancreas does not produce enough insulin -- the hormone that regulates blood sugar levels.

Most people living with diabetes have type 2, which is associated with obesity and other lifestyle factors and emerges in adults and increasingly among children.

All type 1 diabetics need insulin to survive, and generally their access is ensured.

Some 63 million people with type 2 also need the hormone, according to World Health Organization estimates, but only about half of them can access it.

(A.Lehmann--BBZ)